Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 350 participants.
Also called NCT06267391
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 350 participants
- Sponsor
- Endogenex, Inc.
- Registry
-
NCT06267391
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06267391. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-01 (actual); primary completion 2027-02-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Type2diabetes
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Device)
- Endogenex Treatment
- Intervention (Device)
- Sham Procedure
- Lead sponsor
- Endogenex, Inc.
Record details
- Record id
cardio:ct-nct06267391- Content hash
8bf751939be734e013b98be8a8b6a760b5ff053cf5403ceb6ec4510ffbeadc94